{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:22:42Z","timestamp":1740147762371,"version":"3.37.3"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T00:00:00Z","timestamp":1509580800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s11910-017-0807-1","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T23:38:57Z","timestamp":1509579537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Restorative Strategies in Movement Disorders: the Contribution of Imaging"],"prefix":"10.1007","volume":"17","author":[{"given":"Nicholas P.","family":"Lao-Kaim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen F.","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,2]]},"reference":[{"issue":"6","key":"807_CR1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/75705","volume":"3","author":"A Bjorklund","year":"2000","unstructured":"Bjorklund A, Lindvall O. Cell replacement therapies for central nervous system disorders. Nat Neurosci. 2000;3(6):537\u201344.","journal-title":"Nat Neurosci"},{"issue":"8597","key":"807_CR2","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(88)92088-0","volume":"1","author":"ER Hitchcock","year":"1988","unstructured":"Hitchcock ER, Clough C, Hughes R, Kenny B. Embryos and Parkinson\u2019s disease. Lancet. 1988;1(8597):1274.","journal-title":"Lancet"},{"key":"807_CR3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/978-3-7091-9029-6_11","volume":"46","author":"ER Hitchcock","year":"1989","unstructured":"Hitchcock ER, Clough CG, Hughes RC, Kenny BG. Transplantation in Parkinson\u2019s disease: stereotactic implantation of adrenal medulla and foetal mesencephalon. Acta Neurochir Suppl (Wien). 1989;46:48\u201350.","journal-title":"Acta Neurochir Suppl (Wien)"},{"key":"807_CR4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000100224","volume":"54-55","author":"ER Hitchcock","year":"1990","unstructured":"Hitchcock ER, Kenny BG, Clough CG, Hughes RC, Henderson BT, Detta A. Stereotactic implantation of fetal mesencephalon. Stereotact Funct Neurosurg. 1990;54-55:282\u20139.","journal-title":"Stereotact Funct Neurosurg"},{"issue":"6","key":"807_CR5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archneur.1989.00520420033021","volume":"46","author":"O Lindvall","year":"1989","unstructured":"Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, et al. Human-fetal dopamine neurons grafted into the striatum in 2 patients with severe Parkinson\u2019s-disease\u2014a detailed account of methodology and a 6-month follow-up. Arch Neurol. 1989;46(6):615\u201331.","journal-title":"Arch Neurol"},{"issue":"8626\u20138627","key":"807_CR6","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0140-6736(88)90950-6","volume":"2","author":"O Lindvall","year":"1988","unstructured":"Lindvall O, Rehncrona S, Gustavii B, Brundin P, Astedt B, Widner H, et al. Fetal dopamine-rich mesencephalic grafts in Parkinson\u2019s disease. Lancet. 1988;2(8626\u20138627):1483\u20134.","journal-title":"Lancet"},{"issue":"1","key":"807_CR7","first-page":"51","volume":"318","author":"I Madrazo","year":"1988","unstructured":"Madrazo I, Leon V, Torres C, Aguilera MC, Varela G, Alvarez F, et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson\u2019s disease. N Engl J Med. 1988;318(1):51.","journal-title":"N Engl J Med"},{"key":"807_CR8","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/brain\/123.7.1380","volume":"123","author":"P Brundin","year":"2000","unstructured":"Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson\u2019s disease. Brain. 2000;123:1380\u201390.","journal-title":"Brain"},{"issue":"22","key":"807_CR9","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJM199211263272202","volume":"327","author":"CR Freed","year":"1992","unstructured":"Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek E, Qi JX, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson\u2019s disease. N Engl J Med. 1992;327(22):1549\u201355.","journal-title":"N Engl J Med"},{"issue":"3","key":"807_CR10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ana.410380307","volume":"38","author":"TB Freeman","year":"1995","unstructured":"Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson\u2019s disease. Ann Neurol. 1995;38(3):379\u201388.","journal-title":"Ann Neurol"},{"key":"807_CR11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/brain\/122.6.1121","volume":"122","author":"P Hagell","year":"1999","unstructured":"Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, et al. Sequential bilateral transplantation in Parkinson\u2019s disease\u2014effects of the second graft. Brain. 1999;122:1121\u201332.","journal-title":"Brain"},{"issue":"6","key":"807_CR12","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.celrep.2014.05.027","volume":"7","author":"PJ Hallett","year":"2014","unstructured":"Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O. Long-term health of dopaminergic neuron transplants in Parkinson\u2019s disease patients. Cell Rep. 2014;7(6):1755\u201361.","journal-title":"Cell Rep"},{"issue":"2","key":"807_CR13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/archneur.56.2.179","volume":"56","author":"RA Hauser","year":"1999","unstructured":"Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol. 1999;56(2):179\u201387.","journal-title":"Arch Neurol"},{"issue":"3","key":"807_CR14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0014-4886(92)90181-O","volume":"118","author":"BJ Hoffer","year":"1992","unstructured":"Hoffer BJ, Leenders KL, Young D, Gerhardt G, Zerbe GO, Bygdeman M, et al. Eighteen-month course of two patients with grafts of fetal dopamine neurons for severe Parkinson\u2019s disease. Exp Neurol. 1992;118(3):243\u201352.","journal-title":"Exp Neurol"},{"issue":"3","key":"807_CR15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/mds.870130303","volume":"13","author":"JH Kordower","year":"1998","unstructured":"Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson\u2019s disease. Mov Disord. 1998;13(3):383\u201393.","journal-title":"Mov Disord"},{"issue":"17","key":"807_CR16","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJM199504273321702","volume":"332","author":"JH Kordower","year":"1995","unstructured":"Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson\u2019s disease. N Engl J Med. 1995;332(17):1118\u201324.","journal-title":"N Engl J Med"},{"issue":"2","key":"807_CR17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/(SICI)1096-9861(19960624)370:2<203::AID-CNE6>3.0.CO;2-6","volume":"370","author":"JH Kordower","year":"1996","unstructured":"Kordower JH, Rosenstein JM, Collier TJ, Burke MA, Chen EY, Li JM, et al. Functional fetal nigral grafts in a patient with Parkinson\u2019s disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol. 1996;370(2):203\u201330.","journal-title":"J Comp Neurol"},{"issue":"4942","key":"807_CR18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1126\/science.2105529","volume":"247","author":"O Lindvall","year":"1990","unstructured":"Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson\u2019s disease. Science. 1990;247(4942):574\u20137.","journal-title":"Science"},{"issue":"2","key":"807_CR19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ana.410350208","volume":"35","author":"O Lindvall","year":"1994","unstructured":"Lindvall O, Sawle G, Widner H, Rothwell JC, Bjorklund A, Brooks D, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson\u2019s disease. Ann Neurol. 1994;35(2):172\u201380.","journal-title":"Ann Neurol"},{"issue":"2","key":"807_CR20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ana.410310206","volume":"31","author":"O Lindvall","year":"1992","unstructured":"Lindvall O, Widner H, Rehncrona S, Brundin P, Odin P, Gustavii B, et al. Transplantation of fetal dopamine neurons in Parkinson\u2019s disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol. 1992;31(2):155\u201365.","journal-title":"Ann Neurol"},{"issue":"5","key":"807_CR21","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ana.10359","volume":"52","author":"Y Ma","year":"2002","unstructured":"Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol. 2002;52(5):628\u201334.","journal-title":"Ann Neurol"},{"issue":"1","key":"807_CR22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2967\/jnumed.109.066811","volume":"51","author":"Y Ma","year":"2010","unstructured":"Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, et al. Dopamine cell implantation in Parkinson\u2019s disease: long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med. 2010;51(1):7\u201315.","journal-title":"J Nucl Med"},{"issue":"1","key":"807_CR23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jamaneurol.2013.4749","volume":"71","author":"Z Kefalopoulou","year":"2014","unstructured":"Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M, et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol. 2014;71(1):83\u20137.","journal-title":"JAMA Neurol"},{"issue":"2","key":"807_CR24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/096368979600500221","volume":"5","author":"OV Kopyov","year":"1996","unstructured":"Kopyov OV, Jacques D, Lieberman A, Duma CM, Rogers RL. Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson\u2019s disease. Cell Transplant. 1996;5(2):327\u201337.","journal-title":"Cell Transplant"},{"issue":"3","key":"807_CR25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3171\/jns.2002.96.3.0589","volume":"96","author":"I Mendez","year":"2002","unstructured":"Mendez I, Dagher A, Hong M, Gaudet P, Weerasinghe S, McAlister V, et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J Neurosurg. 2002;96(3):589\u201396.","journal-title":"J Neurosurg"},{"issue":"Pt 7","key":"807_CR26","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/brain\/awh510","volume":"128","author":"I Mendez","year":"2005","unstructured":"Mendez I, Sanchez-Pernaute R, Cooper O, Vinuela A, Ferrari D, Bjorklund L, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson\u2019s disease. Brain. 2005;128(Pt 7):1498\u2013510.","journal-title":"Brain"},{"issue":"5","key":"807_CR27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nm1752","volume":"14","author":"I Mendez","year":"2008","unstructured":"Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, et al. Dopamine neurons implanted into people with Parkinson\u2019s disease survive without pathology for 14 years. Nat Med. 2008;14(5):507\u20139.","journal-title":"Nat Med"},{"issue":"Pt 3","key":"807_CR28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/brain\/117.3.487","volume":"117","author":"M Peschanski","year":"1994","unstructured":"Peschanski M, Defer G, N\u2019Guyen JP, Ricolfi F, Monfort JC, Remy P, et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson\u2019s disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain. 1994;117(Pt 3):487\u201399.","journal-title":"Brain"},{"issue":"12","key":"807_CR29","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/16060","volume":"2","author":"P Piccini","year":"1999","unstructured":"Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson\u2019s patient. Nat Neurosci. 1999;2(12):1137\u201340.","journal-title":"Nat Neurosci"},{"issue":"5","key":"807_CR30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/1531-8249(200011)48:5<689::AID-ANA1>3.0.CO;2-N","volume":"48","author":"P Piccini","year":"2000","unstructured":"Piccini P, Lindvall O, Bjorklund A, Brundin P, Hagell P, Ceravolo R, et al. Delayed recovery of movement-related cortical function in Parkinson\u2019s disease after striatal dopaminergic grafts. Ann Neurol. 2000;48(5):689\u201395.","journal-title":"Ann Neurol"},{"issue":"4","key":"807_CR31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.410380406","volume":"38","author":"P Remy","year":"1995","unstructured":"Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin JF, et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol. 1995;38(4):580\u20138.","journal-title":"Ann Neurol"},{"issue":"2","key":"807_CR32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ana.410310207","volume":"31","author":"GV Sawle","year":"1992","unstructured":"Sawle GV, Bloomfield PM, Bjorklund A, Brooks DJ, Brundin P, Leenders KL, et al. Transplantation of fetal dopamine neurons in Parkinson\u2019s disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol. 1992;31(2):166\u201373.","journal-title":"Ann Neurol"},{"issue":"1","key":"807_CR33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ana.410420115","volume":"42","author":"GK Wenning","year":"1997","unstructured":"Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson\u2019s disease. Ann Neurol. 1997;42(1):95\u2013107.","journal-title":"Ann Neurol"},{"issue":"22","key":"807_CR34","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJM199211263272203","volume":"327","author":"H Widner","year":"1992","unstructured":"Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B, et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med. 1992;327(22):1556\u201363.","journal-title":"N Engl J Med"},{"issue":"1","key":"807_CR35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1351-5101.2003.00709.x","volume":"11","author":"WD Heiss","year":"2004","unstructured":"Heiss WD, Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson\u2019s disease. Eur J Neurol. 2004;11(1):5\u201312.","journal-title":"Eur J Neurol"},{"issue":"1","key":"807_CR36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/jcbfm.1993.7","volume":"13","author":"H Kuwabara","year":"1993","unstructured":"Kuwabara H, Cumming P, Reith J, Leger G, Diksic M, Evans AC, et al. Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab. 1993;13(1):43\u201356.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"11","key":"807_CR37","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/mds.23743","volume":"26","author":"M Politis","year":"2011","unstructured":"Politis M, Oertel WH, Wu K, Quinn NP, Pogarell O, Brooks DJ, et al. Graft-induced dyskinesias in Parkinson\u2019s disease: high striatal serotonin\/dopamine transporter ratio. Mov Disord. 2011;26(11):1997\u20132003.","journal-title":"Mov Disord"},{"issue":"128","key":"807_CR38","doi-asserted-by":"crossref","first-page":"128ra41","DOI":"10.1126\/scitranslmed.3003391","volume":"4","author":"M Politis","year":"2012","unstructured":"Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, et al. Serotonin neuron loss and nonmotor symptoms continue in Parkinson\u2019s patients treated with dopamine grafts. Sci Transl Med. 2012;4(128):128ra41.","journal-title":"Sci Transl Med"},{"issue":"38","key":"807_CR39","doi-asserted-by":"crossref","first-page":"38ra46","DOI":"10.1126\/scitranslmed.3000976","volume":"2","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson\u2019s patients with neural transplants. Sci Transl Med. 2010;2(38):38ra46.","journal-title":"Sci Transl Med"},{"issue":"Suppl 1","key":"807_CR40","first-page":"A126","volume":"60","author":"Z Huang","year":"2003","unstructured":"Huang Z, de la Fuente-Fernandez R, Hauser RA, Freeman TB, Sossi V, Olanow CW, et al. Dopaminergic alteration in Parkinson\u2019s patients with off-period dyskinesia following striatal embryonic mesencephalic transplant [Abstract]. Neurology. 2003;60(Suppl 1):A126.","journal-title":"Neurology"},{"issue":"Pt 12","key":"807_CR41","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1093\/brain\/awh649","volume":"128","author":"P Piccini","year":"2005","unstructured":"Piccini P, Pavese N, Hagell P, Reimer J, Bjorklund A, Oertel WH, et al. Factors affecting the clinical outcome after neural transplantation in Parkinson\u2019s disease. Brain. 2005;128(Pt 12):2977\u201386.","journal-title":"Brain"},{"issue":"8","key":"807_CR42","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mds.10463","volume":"18","author":"V Cochen","year":"2003","unstructured":"Cochen V, Ribeiro MJ, Nguyen JP, Gurruchaga JM, Villafane G, Loc\u2019h C, et al. Transplantation in Parkinson\u2019s disease: PET changes correlate with the amount of grafted tissue. Mov Disord. 2003;18(8):928\u201332.","journal-title":"Mov Disord"},{"issue":"4","key":"807_CR43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00259-005-0032-z","volume":"33","author":"O Pogarell","year":"2006","unstructured":"Pogarell O, Koch W, Gildehaus FJ, Kupsch A, Lindvall O, Oertel WH, et al. Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging. 2006;33(4):407\u201311.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"807_CR44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/(SICI)1099-1492(199906)12:4<221::AID-NBM582>3.0.CO;2-Q","volume":"12","author":"BD Ross","year":"1999","unstructured":"Ross BD, Hoang TQ, Bluml S, Dubowitz D, Kopyov OV, Jacques DB, et al. In vivo magnetic resonance spectroscopy of human fetal neural transplants. NMR Biomed. 1999;12(4):221\u201336.","journal-title":"NMR Biomed"},{"issue":"1","key":"807_CR45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1006\/exnr.1999.7073","volume":"158","author":"S Bluml","year":"1999","unstructured":"Bluml S, Kopyov O, Jacques S, Ross BD. Activation of neurotransplants in humans. Exp Neurol. 1999;158(1):121\u20135.","journal-title":"Exp Neurol"},{"issue":"3","key":"807_CR46","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","volume":"54","author":"CW Olanow","year":"2003","unstructured":"Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease. Ann Neurol. 2003;54(3):403\u201314.","journal-title":"Ann Neurol"},{"issue":"3","key":"807_CR47","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/jnnp.2009.201129","volume":"82","author":"RM Richardson","year":"2011","unstructured":"Richardson RM, Freed CR, Shimamoto SA, Starr PA. Pallidal neuronal discharge in Parkinson\u2019s disease following intraputamenal fetal mesencephalic allograft. J Neurol Neurosurg Psychiatry. 2011;82(3):266\u201371.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"807_CR48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","volume":"344","author":"CR Freed","year":"2001","unstructured":"Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease. N Engl J Med. 2001;344(10):710\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"807_CR49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.1075","volume":"50","author":"T Nakamura","year":"2001","unstructured":"Nakamura T, Dhawan V, Chaly T, Fukuda M, Ma Y, Breeze R, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson\u2019s disease. Ann Neurol. 2001;50(2):181\u20137.","journal-title":"Ann Neurol"},{"key":"807_CR50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/bmb\/ldr040","volume":"100","author":"Y Ma","year":"2011","unstructured":"Ma Y, Peng S, Dhawan V, Eidelberg D. Dopamine cell transplantation in Parkinson\u2019s disease: challenge and perspective. Br Med Bull. 2011;100:173\u201389.","journal-title":"Br Med Bull"},{"issue":"7","key":"807_CR51","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nn863","volume":"5","author":"P Hagell","year":"2002","unstructured":"Hagell P, Piccini P, Bjorklund A, Brundin P, Rehncrona S, Widner H, et al. Dyskinesias following neural transplantation in Parkinson\u2019s disease. Nat Neurosci. 2002;5(7):627\u20138.","journal-title":"Nat Neurosci"},{"issue":"3","key":"807_CR52","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/mds.22208","volume":"24","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Gracies JM, Goetz CG, Stoessl AJ, Freeman T, Kordower JH, et al. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson\u2019s disease: a double blind video-based analysis. Mov Disord. 2009;24(3):336\u201343.","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"807_CR53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.brainresbull.2004.10.013","volume":"68","author":"P Hagell","year":"2005","unstructured":"Hagell P, Cenci MA. Dyskinesias and dopamine cell replacement in Parkinson\u2019s disease: a clinical perspective. Brain Res Bull. 2005;68(1\u20132):4\u201315.","journal-title":"Brain Res Bull"},{"issue":"Pt 1","key":"807_CR54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/brain\/119.1.41","volume":"119","author":"GL Defer","year":"1996","unstructured":"Defer GL, Geny C, Ricolfi F, Fenelon G, Monfort JC, Remy P, et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain. 1996;119(Pt 1):41\u201350.","journal-title":"Brain"},{"issue":"Suppl","key":"807_CR55","first-page":"904","volume":"14","author":"PE Greene","year":"1999","unstructured":"Greene PE, Fahn S, Tsai WY, Breeze RE, Eidelberg D, Winfield H, et al. Severe spontaneous dyskinesias: a disabling complication of embryonic dopaminergic tissue implants in a subset of transplanted patients with advanced Parkinson\u2019s disease. Mov Disord. 1999;14(Suppl):904.","journal-title":"Mov Disord"},{"issue":"2\u20134","key":"807_CR56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000029729","volume":"72","author":"DB Jacques","year":"1999","unstructured":"Jacques DB, Kopyov OV, Eagle KS, Carter T, Lieberman A. Outcomes and complications of fetal tissue transplantation in Parkinson\u2019s disease. Stereotact Funct Neurosurg. 1999;72(2\u20134):219\u201324.","journal-title":"Stereotact Funct Neurosurg"},{"issue":"5","key":"807_CR57","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10526","volume":"53","author":"P Piccini","year":"2003","unstructured":"Piccini P, Pavese N, Brooks DJ. Endogenous dopamine release after pharmacological challenges in Parkinson\u2019s disease. Ann Neurol. 2003;53(5):647\u201353.","journal-title":"Ann Neurol"},{"issue":"3","key":"807_CR58","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.nbd.2005.09.008","volume":"21","author":"T Carlsson","year":"2006","unstructured":"Carlsson T, Winkler C, Lundblad MT, Cenci MA, Bjorklund A, Kirik D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol Dis. 2006;21(3):657\u201368.","journal-title":"Neurobiol Dis"},{"issue":"30","key":"807_CR59","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1523\/JNEUROSCI.2079-07.2007","volume":"27","author":"T Carlsson","year":"2007","unstructured":"Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson\u2019s disease. J Neurosci. 2007;27(30):8011\u201322.","journal-title":"J Neurosci"},{"key":"807_CR60","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats. Brain. 2007;130:1819\u201333.","journal-title":"Brain"},{"issue":"Suppl 1","key":"807_CR61","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/mds.22792","volume":"25","author":"M Carta","year":"2010","unstructured":"Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson\u2019s disease. Mov Disord. 2010;25(Suppl 1):S174\u20139.","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"807_CR62","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.brainres.2005.04.019","volume":"1046","author":"T Maeda","year":"2005","unstructured":"Maeda T, Nagata K, Yoshida Y, Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered L-DOPA. Brain Res. 2005;1046(1\u20132):230\u20133.","journal-title":"Brain Res"},{"issue":"Pt 10","key":"807_CR63","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1093\/brain\/awv215","volume":"138","author":"Z Qamhawi","year":"2015","unstructured":"Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson\u2019s disease. Brain. 2015;138(Pt 10):2964\u201373.","journal-title":"Brain"},{"issue":"1","key":"807_CR64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/mds.23895","volume":"27","author":"B Ballanger","year":"2012","unstructured":"Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson\u2019s disease. Mov Disord. 2012;27(1):84\u20139.","journal-title":"Mov Disord"},{"issue":"12","key":"807_CR65","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/mds.22212","volume":"23","author":"I Boileau","year":"2008","unstructured":"Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, et al. Elevated serotonin transporter binding in depressed patients with Parkinson\u2019s disease: a preliminary PET study with [11C]DASB. Mov Disord. 2008;23(12):1776\u201380.","journal-title":"Mov Disord"},{"issue":"21","key":"807_CR66","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/WNL.0b013e3181feb2ab","volume":"75","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 2010;75(21):1920\u20137.","journal-title":"Neurology"},{"key":"807_CR67","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/brain\/awq268","volume":"133","author":"N Pavese","year":"2010","unstructured":"Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinson\u2019s disease is linked to striatal and limbic serotonergic dysfunction. Brain. 2010;133:3434\u201343.","journal-title":"Brain"},{"issue":"5","key":"807_CR68","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease. Nat Med. 2008;14(5):504\u20136.","journal-title":"Nat Med"},{"issue":"16","key":"807_CR69","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/mds.22369","volume":"23","author":"JH Kordower","year":"2008","unstructured":"Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008;23(16):2303\u20136.","journal-title":"Mov Disord"},{"issue":"3","key":"807_CR70","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/096368979700600304","volume":"6","author":"JH Kordower","year":"1997","unstructured":"Kordower JH, Styren S, Clarke M, DeKosky ST, Olanow CW, Freeman TB. Fetal grafting for Parkinson\u2019s disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant. 1997;6(3):213\u20139.","journal-title":"Cell Transplant"},{"issue":"1","key":"807_CR71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ana.24820","volume":"81","author":"JH Kordower","year":"2017","unstructured":"\u2022 Kordower JH, Goetz CG, Chu Y, Halliday GM, Nicholson DA, Musial TF, et al. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017;81(1):46\u201357. This single subject post-mortem study showed that robust graft survival in Parkinson\u2019s disease does not necessarily translate to clinical improvement.","journal-title":"Ann Neurol"},{"issue":"1","key":"807_CR72","first-page":"83","volume":"1","author":"Z Kurowska","year":"2011","unstructured":"Kurowska Z, Englund E, Widner H, Lindvall O, Li JY, Brundin P. Signs of degeneration in 12-22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson\u2019s disease. J Park Dis. 2011;1(1):83\u201392.","journal-title":"J Park Dis"},{"issue":"23","key":"807_CR73","doi-asserted-by":"crossref","first-page":"6544","DOI":"10.1073\/pnas.1605245113","volume":"113","author":"W Li","year":"2016","unstructured":"\u2022\u2022 Li W, Englund E, Widner H, Mattsson B, van Westen D, Latt J, et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci U S A. 2016;113(23):6544\u20139. This post-mortem study of a single Parkinson\u2019s patient who received striatal implant showed extensive graft-derived dopaminergic innervation more than two decades after implantation, but alpha-synuclein inclusions were seen in 11\u201312% of the grafted neurons.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1","key":"807_CR74","first-page":"206","volume":"29","author":"A Kikuchi","year":"2014","unstructured":"Kikuchi A, Okamura N, Tashiro M, Hasegawa T, Sugeno N, Baba T, et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labeled 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole positron emission tomography in Parkinson\u2019s disease [Abstract]. Mov Disord. 2014;29(Suppl 1):206.","journal-title":"Mov Disord"},{"key":"807_CR75","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/brain\/awq091","volume":"133","author":"A Kikuchi","year":"2010","unstructured":"Kikuchi A, Takeda A, Okamura N, Tashiro M, Hasegawa T, Furumoto S, et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain. 2010;133:1772\u20138.","journal-title":"Brain"},{"issue":"2","key":"807_CR76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055031","volume":"8","author":"DP Bagchi","year":"2013","unstructured":"Bagchi DP, Yu L, Perlmutter JS, Xu J, Mach RH, Tu Z, et al. Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One. 2013;8(2):e55031.","journal-title":"PLoS One"},{"issue":"9","key":"807_CR77","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2967\/jnumed.113.136515","volume":"55","author":"M Shah","year":"2014","unstructured":"\u2022 Shah M, Seibyl J, Cartier A, Bhatt R, Catafau AM. Molecular imaging insights into neurodegeneration: focus on alpha-synuclein radiotracers. J Nucl Med. 2014;55(9):1397\u2013400. An update on the development of alpha-synuclein PET tracers, which could herald a breakthrough in molecular imaging in Parkinson\u2019s disease.","journal-title":"J Nucl Med"},{"key":"807_CR78","unstructured":"Tsika E, Davranche A, Molette J, Gaballieri E, Papin S, Nampally S, et al. Novel PET tracers of alpha-synuclein for the diagnosis of Parkinson\u2019s disease [abstract]. Mov Disord. 2016;31(Suppl 2)"},{"issue":"5","key":"807_CR79","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","volume":"9","author":"SS Gill","year":"2003","unstructured":"Gill SS, Patel NK, Hotton GR, O\u2019Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9(5):589\u201395.","journal-title":"Nat Med"},{"issue":"3","key":"807_CR80","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","volume":"59","author":"AE Lang","year":"2006","unstructured":"Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59(3):459\u201366.","journal-title":"Ann Neurol"},{"issue":"13","key":"807_CR81","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1212\/WNL.0b013e3182a55ea5","volume":"81","author":"NK Patel","year":"2013","unstructured":"Patel NK, Pavese N, Javed S, Hotton GR, Brooks DJ, Gill SS. Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation. Neurology. 2013;81(13):1176\u20138.","journal-title":"Neurology"},{"issue":"6608","key":"807_CR82","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/384467a0","volume":"384","author":"PT Kotzbauer","year":"1996","unstructured":"Kotzbauer PT, Lampe PA, Heuckeroth RO, Golden JP, Creedon DJ, Johnson EM Jr, et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature. 1996;384(6608):467\u201370.","journal-title":"Nature"},{"issue":"12","key":"807_CR83","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks Jr","year":"2010","unstructured":"Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12):1164\u201372.","journal-title":"Lancet Neurol"},{"issue":"2","key":"807_CR84","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.24436","volume":"78","author":"C Warren Olanow","year":"2015","unstructured":"Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol. 2015;78(2):248\u201357.","journal-title":"Ann Neurol"},{"issue":"6","key":"807_CR85","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol. 1985;44(6):559\u201377.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"Pt 12","key":"807_CR86","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","volume":"122","author":"TC Andrews","year":"1999","unstructured":"Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, et al. Huntington\u2019s disease progression. PET and clinical observations. Brain. 1999;122(Pt 12):2353\u201363.","journal-title":"Brain"},{"issue":"Pt 5","key":"807_CR87","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awg119","volume":"126","author":"N Pavese","year":"2003","unstructured":"Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington\u2019s disease: a PET study. Brain. 2003;126(Pt 5):1127\u201335.","journal-title":"Brain"},{"issue":"Pt 6","key":"807_CR88","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","volume":"119","author":"A Antonini","year":"1996","unstructured":"Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington\u2019s disease. Brain. 1996;119(Pt 6):2085\u201395.","journal-title":"Brain"},{"issue":"3","key":"807_CR89","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0306-4522(96)00657-4","volume":"79","author":"RA Fricker","year":"1997","unstructured":"Fricker RA, Torres EM, Hume SP, Myers R, Opacka-Juffrey J, Ashworth S, et al. The effects of donor stage on the survival and function of embryonic striatal grafts in the adult rat brain. II. Correlation between positron emission tomography and reaching behaviour. Neuroscience. 1997;79(3):711\u201321.","journal-title":"Neuroscience"},{"issue":"2","key":"807_CR90","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/mds.870110202","volume":"11","author":"N Quinn","year":"1996","unstructured":"Quinn N, Brown R, Craufurd D, Goldman S, Hodges J, Kieburtz K, et al. Core Assessment Program for Intracerebral Transplantation in Huntington\u2019s Disease (CAPIT-HD). Mov Disord. 1996;11(2):143\u201350.","journal-title":"Mov Disord"},{"issue":"1","key":"807_CR91","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0893-133X(87)90004-2","volume":"1","author":"P Seeman","year":"1987","unstructured":"Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s diseases. Neuropsychopharmacology. 1987;1(1):5\u201315.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"807_CR92","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/jnnp.2007.142380","volume":"79","author":"I Reuter","year":"2008","unstructured":"Reuter I, Tai YF, Pavese N, Chaudhuri KR, Mason S, Polkey CE, et al. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2008;79(8):948\u201351.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9246","key":"807_CR93","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(00)03310-9","volume":"356","author":"AC Bachoud-Levi","year":"2000","unstructured":"Bachoud-Levi AC, Remy P, Nguyen JP, Brugieres P, Lefaucheur JP, Bourdet C, et al. Motor and cognitive improvements in patients with Huntington\u2019s disease after neural transplantation. Lancet. 2000;356(9246):1975\u20139.","journal-title":"Lancet"},{"issue":"4","key":"807_CR94","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1474-4422(06)70381-7","volume":"5","author":"AC Bachoud-Levi","year":"2006","unstructured":"Bachoud-Levi AC, Gaura V, Brugieres P, Lefaucheur JP, Boisse MF, Maison P, et al. Effect of fetal neural transplants in patients with Huntington\u2019s disease 6 years after surgery: a long-term follow-up study. Lancet Neurol. 2006;5(4):303\u20139.","journal-title":"Lancet Neurol"},{"issue":"Pt 1","key":"807_CR95","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/brain\/awh003","volume":"127","author":"V Gaura","year":"2004","unstructured":"Gaura V, Bachoud-Levi AC, Ribeiro MJ, Nguyen JP, Frouin V, Baudic S, et al. Striatal neural grafting improves cortical metabolism in Huntington\u2019s disease patients. Brain. 2004;127(Pt 1):65\u201372.","journal-title":"Brain"},{"issue":"5","key":"807_CR96","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1212\/WNL.58.5.687","volume":"58","author":"RA Hauser","year":"2002","unstructured":"Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, et al. Bilateral human fetal striatal transplantation in Huntington\u2019s disease. Neurology. 2002;58(5):687\u201395.","journal-title":"Neurology"},{"issue":"2","key":"807_CR97","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ana.20564","volume":"58","author":"S Furtado","year":"2005","unstructured":"Furtado S, Sossi V, Hauser RA, Samii A, Schulzer M, Murphy CB, et al. Positron emission tomography after fetal transplantation in Huntington\u2019s disease. Ann Neurol. 2005;58(2):331\u20137.","journal-title":"Ann Neurol"},{"issue":"25","key":"807_CR98","doi-asserted-by":"crossref","first-page":"13877","DOI":"10.1073\/pnas.97.25.13877","volume":"97","author":"TB Freeman","year":"2000","unstructured":"Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, et al. Transplanted fetal striatum in Huntington\u2019s disease: phenotypic development and lack of pathology. Proc Natl Acad Sci U S A. 2000;97(25):13877\u201382.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"30","key":"807_CR99","doi-asserted-by":"crossref","first-page":"12483","DOI":"10.1073\/pnas.0904239106","volume":"106","author":"F Cicchetti","year":"2009","unstructured":"Cicchetti F, Saporta S, Hauser RA, Parent M, Saint-Pierre M, Sanberg PR, et al. Neural transplants in patients with Huntington\u2019s disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A. 2009;106(30):12483\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"37","key":"807_CR100","doi-asserted-by":"crossref","first-page":"E104","DOI":"10.1073\/pnas.0908169106","volume":"106","author":"PJ Hallett","year":"2009","unstructured":"Hallett PJ, Cooper O, Isacson O. No evidence for disease-like processes in fetal transplants. Proc Natl Acad Sci U S A. 2009;106(37):E104. author reply E5","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"807_CR101","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1759-1961.2011.00018.x","volume":"2","author":"SS Krebs","year":"2011","unstructured":"Krebs SS, Trippel M, Prokop T, Omer TN, Landwehrmeyer B, Weber WA, et al. Immune response after striatal engraftment of fetal neuronal cells in patients with Huntington\u2019s disease: consequences for cerebral transplantation programs. Clin Exp Neurol. 2011;2(2):25\u201332.","journal-title":"Clin Exp Neurol"},{"issue":"9","key":"807_CR102","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jnnp-2013-306533","volume":"85","author":"M Paganini","year":"2014","unstructured":"Paganini M, Biggeri A, Romoli AM, Mechi C, Ghelli E, Berti V, et al. Fetal striatal grafting slows motor and cognitive decline of Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2014;85(9):974\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"807_CR103","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jnnp-2012-302441","volume":"84","author":"RA Barker","year":"2013","unstructured":"Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, et al. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2013;84(6):657\u201365.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 3","key":"807_CR104","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/brain\/awq328","volume":"134","author":"F Cicchetti","year":"2011","unstructured":"Cicchetti F, Soulet D, Freeman TB. Neuronal degeneration in striatal transplants and Huntington\u2019s disease: potential mechanisms and clinical implications. Brain. 2011;134(Pt 3):641\u201352.","journal-title":"Brain"},{"issue":"Pt 2","key":"807_CR105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/brain\/aws359","volume":"136","author":"G Cisbani","year":"2013","unstructured":"\u2022 Cisbani G, Freeman TB, Soulet D, Saint-Pierre M, Gagnon D, Parent M, et al. Striatal allografts in patients with Huntington\u2019s disease: impact of diminished astrocytes and vascularization on graft viability. Brain. 2013;136(Pt 2):433\u201343. This was the first study to look at the effect of vascularisation of striatal allograft on graft survival in Huntington\u2019s disease","journal-title":"Brain"},{"key":"807_CR106","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/bs.pbr.2016.12.011","volume":"230","author":"AC Bachoud-Levi","year":"2017","unstructured":"Bachoud-Levi AC. From open to large-scale randomized cell transplantation trials in Huntington\u2019s disease: lessons from the multicentric intracerebral grafting in Huntington\u2019s disease trial (MIG-HD) and previous pilot studies. Prog Brain Res. 2017;230:227\u201361.","journal-title":"Prog Brain Res"},{"key":"807_CR107","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.pbr.2016.11.011","volume":"230","author":"A Kirkeby","year":"2017","unstructured":"Kirkeby A, Parmar M, Barker RA. Strategies for bringing stem cell-derived dopamine neurons to the clinic: a European approach (STEM-PD). Prog Brain Res. 2017;230:165\u201390.","journal-title":"Prog Brain Res"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-017-0807-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-017-0807-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-017-0807-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T09:08:01Z","timestamp":1570266481000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-017-0807-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,2]]},"references-count":107,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1007\/s11910-017-0807-1","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"type":"print","value":"1528-4042"},{"type":"electronic","value":"1534-6293"}],"subject":[],"published":{"date-parts":[[2017,11,2]]},"article-number":"98"}}